A digital assessment, triage, management and monitoring tool to support clinicians to support Long COVID patients and for patients to track their own recovery and rehabilitation.
C19-YRS is a validated screening tool used to assess the severity of common persistent symptoms identified in patients after contracting COVID-19, also known as ‘long COVID’ or ‘post-COVID syndrome’. The self-reporting tool has been developed by clinical academics at The University of Leeds using research gathered across the West Yorkshire region. The tool has been recommended for routine use by NHS England in their National Guidance for post-COVID syndrome assessment and also recognised by NICE in their rapid guidelines for managing the long-term effects of COVID-19. More details of the benefits offered by C19-YRS can be viewed through the product brochure accessible here.
Long COVID is a term used to describe a new and emerging condition faced by patients presenting with symptoms that develop during or after contracting COVID-19 and persist for more than 4 weeks according to NICE. The syndrome is still not yet fully understood, with symptoms of breathlessness, cough and severe fatigue being amongst the most prevalent symptoms. As of January 24th 2021 the World Health Organisation estimates there have 97.4 million confirmed cases of (acute) COVID-19, with the Office for National Statistics estimating that:
Around 20% of patients testing positive for COVID-19 exhibit symptoms for a period of 5 weeks or longer
Around 10% of patients testing positive for COVID-19 exhibit symptoms for a period of 12 weeks or longer
Scoring of symptom severity and functional disability performance
Easy to use, secure and scalable platform to oversee patients
User friendly with visual aids for patients to monitor recovery progress
The system is free to purchase for all
ELAROS’ C19-YRS boasts a secure web portal for clinicians to set up and manage patients to assist with the initial triage, assessment and short-to-long-term monitoring process using graded scores for a spectrum of symptoms and grouped scores
for symptom severity, functional disability and overall health. Extensive reporting tools help support health organisations better deploy, evidence and account for the complex mix of resources used for long COVID patients.
This is a not for profit initiative for all NHS organisations.
Patients can access the questionnaire following referral from their healthcare professional, available on iOS and Android or any internet web browser, allowing them to track their condition with a quantitative assessment of improvement or deterioration. The platform seeks to improve patient outcomes, clinical intervention methods and help to understand long COVID as a condition by providing The University of Leeds’ research team with anonymised data to further validate the scale and develop a robust measure of the condition.
The system provides a secure, scalable solution to manage multiple patients on a single platform and is free at the point of use for all NHS organisations.
The C19-YRS captures data automatically and generates a report to clinicians in real time, offering powerful reporting tools to both clinicians and patients.
Features of the clinical web portal
Features of the patient app
Partners and Endorsements
ELAROS’ C19-YRS was rapidly developed to a high standard, by working closely with clinical researchers at University of Leeds and Pipe & Piper Ltd to pivot ELAROS’ existing CE-marked Digital Bladder Diary platform. The paper C19-YRS self-report is being slowly adopted by NHS Trusts across the UK as of December 2020. ELAROS’ digital C19-YRS aims to improve the Long COVID patient care pathway and offer patients and clinicians an enhanced, secure, remote digital alternative solution.
C19-YRS was developed with support from The University of Leeds, Leeds Teaching Hospitals NHS Trust, Leeds Community Healthcare NHS Trust, Airedale and Hull NHS Trusts.
Recommended for routine use by NHS England in their National Guidance for post-COVID syndrome assessment and has been recognised by NICE in their rapid guidelines for managing the long-term effects of COVID-19 as a clinically relevant tool, requesting further validation and development with patients and clinicians.